Sugi Predict

Sugi Predict / Compounds / SCHEMBL3613205

SCHEMBL3613205

SCHEMBL3613205

CC(C)(C)OC(=O)N1CCCN(c2ccc(N)c(N)c2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ PDK2 Q15119 1/20 0.53
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ SMARCA2 P51531 1/20 0.48
▸ SMARCA4 P51532 1/20 0.48
▸ PBRM1 Q86U86 1/20 0.48
▸ GPR119 Q8TDV5 6/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ CKS1B P61024 1/20 0.47
▸ SKP1 P63208 1/20 0.47
▸ SKP2 Q13309 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NAMPT P43490 1/20 0.47
▸ CYP2C19 P33261 1/20 0.46
▸ SUV39H2 Q9H5I1 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214944 0.95 MAPT (0.62) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL30565931 0.95 MAPT (0.62) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL22652114 0.90 MAPT (0.55) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL2731570 0.88 LMNA (0.53) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL22652071 0.88 MAPT (0.53) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL23293364 0.86 MAPT (0.61) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL31157974 0.86 MAPT (0.61) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL15938050 0.86 MAPT (0.51) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL3194630 0.86 MAPT (0.61) MAPTALDH1A1LMNAPDK2MEN1
SCHEMBL13548454 0.85 MAPT (0.61) MAPTALDH1A1LMNAPDK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283475-B1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2019-10-16 — — EP disclosed
US-10179777-B2 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives MERCK PATENT GMBH (DE) 2019-01-15 — — US disclosed
US-20180099947-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2018-04-12 — — US disclosed
US-20180099947-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2018-04-12 — — US disclosed
WO-2016165808-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2016-10-20 — — WO disclosed
US-7718650-B2 Aryl sulfonamide compounds for treating obesity BIOVITRUM AB (SE) 2010-05-18 — — US disclosed
US-7566715-B2 Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system BIOVITRUM AB (SE) 2009-07-28 — — US disclosed
US-20080096873-A1 NEW COMPOUNDS BIOVITRUM AB, A SWEDEN CORPORATION 2008-04-24 — — US disclosed
US-7319097-B2 Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride BIOVITRUM AB (SE) 2008-01-15 — — US disclosed
US-7173035-B2 Arylsulfonamide compounds BIOVITRUM AB (SE) 2007-02-06 — — US disclosed
US-20060009446-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2006-01-12 — — US disclosed
US-20050288275-A1 New compounds BIOVITRUM AB, A SWEDEN CORPORATION 2005-12-29 — — US disclosed
US-6969710-B2 Compounds BIOVITRUM AB (SE) 2005-11-29 — — US disclosed
EP-1406884-A1 ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2004-04-14 — — EP disclosed
US-20030149019-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-07 — — US disclosed
US-20030149020-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-07 — — US disclosed
WO-2002092585-A1 NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS BIOVITRUM AB (SE) 2002-11-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149020-A1 New compounds GPR119, SULT2A1, NAT1 MAPT 2577/4885ALDH1A1 438/4885LMNA 3478/4885
US-20030149019-A1 New compounds GPR119, SULT2A1, NAT1 MAPT 2577/4885ALDH1A1 438/4885LMNA 3478/4885
US-20060009446-A1 New compounds GPR119, SULT2A1, STS MAPT 2697/4885ALDH1A1 818/4885LMNA 3475/4885
US-20080096873-A1 NEW COMPOUNDS GPR119, SULT2A1, STS MAPT 2697/4885ALDH1A1 818/4885LMNA 3475/4885
US-10179777-B2 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives ALK, ABL2, ACVR1 MAPT 4062/4885ALDH1A1 75/4885LMNA 1061/4885
US-20050288275-A1 New compounds GPR119, SULT2A1, STS MAPT 2697/4885ALDH1A1 818/4885LMNA 3475/4885
US-20180099947-A1 3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRIDIN-2-ONE DERIVATIVES ALK, ABL2, ACVR1 MAPT 4062/4885ALDH1A1 75/4885LMNA 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.